RICARDO VIERA: Open Payments
NPI 1639570088 · MIAMI, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,026 in 81 payments from 16 companies in 2025. Trend: 2023 $128 · 2024 $1,437 · 2025 $2,026
Food & beverage: $1,936Education: $90
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 21 | $540 |
| Astellas Pharma US Inc | 6 | $238 |
| GlaxoSmithKline, LLC. | 6 | $191 |
| Lilly USA, LLC | 12 | $187 |
| Abbott Laboratories | 5 | $148 |
| Novo Nordisk Inc | 6 | $126 |
| PFIZER INC. | 4 | $101 |
| Corcept Therapeutics | 4 | $95 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $80 |
| Dexcom, Inc. | 4 | $77 |
Products named: TRELEGY ELLIPTA, FARXIGA, Veozah, FREESTYLE LIBRE 3, MOUNJARO, ELIQUIS, Korlym, Kerendia.
Industry payments across FL — which companies pay providers there.
